Abstract 1762P
Background
Dissemination of research results, including data from clinical trials, is one of the essential responsibilities of all scientists. Moreover, whole community of researchers, patients, and general public, should have access to research data at earliest possible moment. However, significant delay between completion of the study and publication of its results has been observed; thus, we aimed to analyze the time from database lockdown to publication and factors that might be associated with it.
Methods
We analyzed all original publications reporting any clinical data published in 2020 and 2021 in 2 leading oncological journal – Journal of Clinical Oncology (JCO) and Annals of Oncology (AoO). Information of cut-off (database lock) date, publication date, type of the study and its sponsor has been extracted. Descriptive statistics, t-test and chi-square tests were used for statistical analyses.
Results
Overall, 652 articles (482 from JCO, 170 from AoO) has been identified - 63% (411) reported results of clinical trials, 47% (193) of them reporting data from clinical trials. Only 52.3% (341) of trials reported the cut-off date. Reports from clinical trials reported cut-off date more often than other studies (65.5% vs 29.9%, p<0.001). Median time from data cut-off to publication (PT) was 15.4 months (range 1.2-130.8), with PT of 12-24 months and >24 months being 45.2% (154) and 22.6% (77), respectively. Reports of studies other than clinical trials had PT>24m more often than clinical trials (36.1% vs 19%; p=0.003). Commercially sponsored studies reported cut-off date more often than academic studies (79.2% vs 41.4%; p<0.001) but there was no difference in PT depending on type of sponsor (p=0.170).
Conclusions
Despite presence of reporting guidelines, significant proportion of scientific publications do not report exact date of data cut-off or last follow-up what make difficult to assess topicality and maturity of data. Moreover, nearly one-quarter of publications report results that are older than 2 years. Causes leading to such disproportion and publication of outdated results may lead on the authors’, editors’ or publishers’ side and need to be studied in more depth to ensure timely publication of relevant research data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Sobczuk: Financial Interests, Personal, Other, Travel grant: Novartis; Financial Interests, Personal, Other, Travel Grant: MSD, BMS; Financial Interests, Personal, Invited Speaker: Swixx BioPharma, BMS, Gilead; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Stocks/Shares: CelonPharma; Non-Financial Interests, Institutional, Product Samples: Immutep; Non-Financial Interests, Leadership Role, Board Member, Chair of Young Oncologists Section: Polish Society of Clinical Oncology. P. Rutkowski: Financial Interests, Personal, Invited Speaker, honoraria for lectures: MSD, BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Merck, Sanofi, Blueprint Medicines, Philogen; Financial Interests, Personal, Invited Speaker: Merck, Sanofi, Novartis, AstraZeneca; Financial Interests, Institutional, Research Grant, research grant for ISS: Pfizer; Financial Interests, Institutional, Funding, research grant for institution: BMS; Non-Financial Interests, Member of Board of Directors: Polish Society of Surgical Oncology; Non-Financial Interests, Member of Board of Directors, President: Polish Oncological Society. All other authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23